Indications, diagnostic tests and Helicobacter pylori eradication therapy. Recommendations by the 2nd Spanish Consensus Conference

• Published in: Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva Vol. 97; no. 5; pp. 348 - 374
• Main Authors: Monés, J, Gisbert, J P, Borda, F, Domínguez-Muñoz, E
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Spain Sociedad Española de Patología Digestiva 01.05.2005
• Subjects: Gastroenterology & Hepatology; Geriatrics & Gerontology; Helicobacter Infections - complications; Helicobacter Infections - diagnosis; Helicobacter Infections - drug therapy; Helicobacter pylori; Humans; Infectious Diseases; Oncology; Pathology; Pharmacology & Pharmacy; Radiology, Nuclear Medicine & Medical Imaging; Surgery; Therapy; Clarithromycin; Amoxicilina; Indicaciones de erradicación; Diagnóstico; Lansoprazol; Esomeprazol; Rabeprazole; Eradication; Indications for eradication; Inhibidores de la bomba de protones (IBP); Ranitidine-bismuth citrate; Metronidazol; Helicobacter pylori; Erradicación; Ranitidina-citrato de bismuto; Omeprazol; Tratamiento; Diagnosis; Pantoprazole; Proton pump inhibitors (PPIs); Omeprazole; Pantoprazol; Esomeprazole; Amoxicillin; Rabeprazol; Metronidazole; Claritromicina; Lansoprazole
• DOI: 10.4321/S1130-01082005000500007
• ISSN: 1130-0108

The results of the 2nd Spanish Consensus Conference for appropriate practice regarding indications for eradication, diagnostic tests, and therapy regimens for Helicobacter pylori infection are summarized. The Conference was based on literature searches in Medline, abstracts from three international meetings, and abstracts from national meetings. Results were agreed upon and approved by the whole group. Results are supplemented by evidence grades and recommendation levels according to the classification used in the Clinical Practice Guidelines issued by Cochrane Collaboration. Convincing indications (peptic ulcer, duodenal erosions with no history of ASA or NSAIDs, MALT lymphoma), and not so convincing indications (functional dyspepsia, patients receiving low-dose ASA for platelet aggregation, gastrectomy stump in patients operated on for gastric cancer, first-degree relatives of patients with gastric cancer, lymphocytic gastritis, and Ménétrier s disease) for H. pylori eradication are discussed. Diagnostic recommendations for various clinical conditions (peptic ulcer, digestive hemorrhage secondary to ulcer, eradication control, patients currently or recently receiving antibiotic or antisecretory therapy), as well as diagnostic tests requiring biopsy collection (histology, urease fast test, and culture) when endoscopy is needed for clinical diagnosis, and non-invasive tests requiring no biopsy collection (13C-urea breath test, serologic tests, and fecal antigen tests) when endoscopy is not needed are also discussed. As regards treatment, first-choice therapies (triple therapy using a PPI and two antibiotics), therapy length, quadruple therapy, and a number of novel antibiotic options as "rescue" therapy are prioritized, the fact that prolonging PPI therapy following effective eradication is unnecessary for patients with duodenal ulcer but not for all gastric ulcers is documented, the fact that cultures and antibiograms are not needed for all eradicating therapies is indicated, and finally the test and treat strategy is considered adequate, however only under certain circumstances.